Skip to main content
. Author manuscript; available in PMC: 2023 Jan 1.
Published in final edited form as: Adv Drug Deliv Rev. 2021 Nov 9;180:114042. doi: 10.1016/j.addr.2021.114042

Fig. 3.

Fig. 3.

RBP-based regulation of RNAs for cancer therapeutics. RBPs binding to oncogenic or tumor suppressor mRNAs results in an altered expression of the encoded cancer-related proteins, thereby affecting cellular metabolisms such as tumor proliferation or apoptosis. The binding of RBPs with essential mRNAs, which encodes for transcription factors or post-transcriptional modulators, has profound implications in cellular physiology as it can control cell cycle progression and gene expression levels. RBPs can also regulate the expression of non-coding RNAs (ncRNA), which in turn affect the expression of the genes regulated by the ncRNA. Figure created using BioRender.com.